HC Wainwright Has Bullish Forecast for Nuvalent Q1 Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Nuvalent in a research note issued on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.26) per share for the quarter, up from their previous estimate of ($1.53). HC Wainwright currently has a “Buy” rating and a $155.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at $2.11 EPS and FY2030 earnings at $2.59 EPS.

A number of other equities research analysts also recently commented on NUVL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research report on Thursday, January 22nd. JPMorgan Chase & Co. decreased their price target on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Guggenheim lifted their price target on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Canaccord Genuity Group started coverage on shares of Nuvalent in a research note on Wednesday, November 12th. They set a “buy” rating and a $126.00 price objective for the company. Finally, The Goldman Sachs Group increased their price objective on shares of Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Fifteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Nuvalent currently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

Nuvalent Stock Performance

Shares of NUVL opened at $100.13 on Thursday. Nuvalent has a fifty-two week low of $55.53 and a fifty-two week high of $113.01. The company has a market capitalization of $7.28 billion, a PE ratio of -17.12 and a beta of 1.32. The stock has a fifty day moving average of $103.14 and a two-hundred day moving average of $95.72.

Institutional Investors Weigh In On Nuvalent

Several large investors have recently made changes to their positions in NUVL. Seven Fleet Capital Management LP acquired a new position in shares of Nuvalent during the 4th quarter valued at $1,268,000. T. Rowe Price Investment Management Inc. increased its holdings in Nuvalent by 29.3% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,319,963 shares of the company’s stock valued at $132,776,000 after purchasing an additional 298,727 shares in the last quarter. Invesco Ltd. raised its position in Nuvalent by 1,201.4% in the fourth quarter. Invesco Ltd. now owns 439,300 shares of the company’s stock valued at $44,189,000 after purchasing an additional 405,543 shares during the period. XTX Topco Ltd acquired a new position in shares of Nuvalent during the fourth quarter worth about $1,559,000. Finally, Ikarian Capital LLC acquired a new position in shares of Nuvalent during the fourth quarter worth about $5,995,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Insider Buying and Selling

In related news, insider Henry E. Pelish sold 2,664 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $97.17, for a total value of $258,860.88. Following the transaction, the insider owned 65,888 shares in the company, valued at approximately $6,402,336.96. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Christopher Durant Turner sold 4,236 shares of Nuvalent stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $412,247.52. Following the transaction, the insider directly owned 58,311 shares in the company, valued at approximately $5,674,826.52. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 76,463 shares of company stock worth $7,722,489. Corporate insiders own 10.20% of the company’s stock.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: HC Wainwright raised quarterly EPS forecasts for Q1–Q4 2026 and mid‑2026 quarters (cuts to expected losses: Q1 to ($1.26), Q2 to ($1.21), Q3 to ($1.16), Q4 to ($0.94)), and improved FY2026 to ($4.57) from a larger loss — signaling an expectation for accelerating progress toward profitability. MarketBeat article
• Positive Sentiment: HC Wainwright increased long‑range profitability views for FY2028 and FY2030 (FY2028 to $2.11 EPS from $1.75; FY2030 at $2.59), indicating confidence in Nuvalent’s longer-term product/market potential. MarketBeat article
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $155 price target — a bullish signal that may support upside if operational/clinical catalysts meet expectations, but it’s based on multi‑year recovery assumptions. MarketBeat article
• Neutral Sentiment: Market context: the company still shows a consensus near‑term full‑year loss (current consensus FY2026 ≈ ($3.86) per share) and a relatively high beta, so revisions can produce outsized intraday moves. MarketBeat article
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2029 forecasts (FY2027 to ($2.06) from ($1.69); FY2029 to $6.52 from $6.77), showing some downward revision to intermediate/out‑year expectations and adding uncertainty to the profit ramp timeline. MarketBeat article

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.